Navigation Links
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Date:9/25/2011

c and rapidly progressive and can result in right ventricular heart failure and death(4). An estimated 260,000 people are affected worldwide(3) and approximately half of the people diagnosed with PAH die within five years,(10).

"If approved, QTI571 has the potential to provide a further treatment option for patients where current therapies are not providing sufficient benefit in the treatment of this life-threatening disease," said David Epstein, Division Head of Novartis Pharmaceuticals. "Novartis has a strong and growing portfolio of respiratory medicines, and we are committed to expanding the support we offer to patients suffering from a number of respiratory and pulmonary disorders."

QTI571 is an oral therapy that works by inhibiting the activity of proliferative factors including platelet-derived growth factor (PDGF) which is thought to be involved, along with its receptor, in the progression of PAH(10,11). In patients with this disease, PDGF may cause smooth muscle cells in the pulmonary arteries to multiply, restricting blood flow and increasing resistance in these arteries(12).

Safety data showed that the overall incidence of adverse events was similar for QTI571 and for placebo(1). Serious adverse events and discontinuations due to serious adverse events were more frequent with QTI571(1). Adverse events were as expected for this patient population and class of drug, and were similar to those previously reported with QTI571(13).

IMPRES was a 24-week randomized placebo-controlled, double-blind, multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of patients with PAH(1). The study involved a total of 202 patients with elevated PVR of >800 dynes.sec.cm-5 despite treatment with at least two other specific PAH medications (i.e. endothelin receptor antagonists, phosphodiesterase-5 inhibitors and/or prostacyclins)(1).

Treatment was initiated at a dose of 2
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 DePuy Synthes ... with Radlink, Inc., an emerging global leader in ... guidance with its hip replacement systems. The agreement ... help improve patient outcomes, increase patient satisfaction and ... the 81st annual meeting of the American Academy ...
(Date:3/26/2015)... 2015  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... preclinical and clinical data showcasing its deep ... for Cancer Research (AACR) Annual Meeting being ... The presentations describe recent data from Merrimack,s ... as well as oral presentations on Phase ...
(Date:3/26/2015)... Kalifornien, 26. März 2015 Finesse ... die sich speziell an Innovatoren, Visionäre und ... Die zweitägige Konferenz für geladene Gäste ... im Hyatt Regency in Downtown ... Forum werden führende Akteure der Biowissenschaften die ...
Breaking Medicine Technology:DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting 2Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting 3Finesse Solutions kündigt Cellworld 2015 an 2
(Date:3/26/2015)... 26, 2015 Building off their ... medical education, the Cardiometabolic Risk Summit ... Tulane University are proud to announce a ... The interdisciplinary program , which ultimately grants ... designed for physicians, nurse practitioners, physician assistants, registered ...
(Date:3/26/2015)... Visiting Nurse Association of Northern ... gala fundraiser, Lighting the Way, Brightening the Day, on ... Madison Hotel in Morristown, NJ. , Guests will ... musician Rio Clemente, delightful cuisine, an extensive silent auction ... Additionally, two prestigious awards will be presented to this ...
(Date:3/26/2015)... 26, 2015 Dr. Alex Rabinovich and ... announce expanded offerings for Bay Area patients considering dental ... Center has long been a top-rated center, serving primarily ... to meet the strong demand by others throughout Northern ... a top-rated dental implant facility in San Francisco,”explained Dr. ...
(Date:3/26/2015)... 26, 2015 Innovative research and ... and preventing often fatal ruptures, says The Bee ... raising awareness of brain aneurysms and funding innovative ... captured national attention with the death of ... died last Friday after suffering a ruptured brain ...
(Date:3/26/2015)... The National League for Nursing, ... , has announced its partnership with Questionmark®, a ... corporations to accurately and securely measure knowledge, skills, ... Utilizing Questionmark’s state-of-the-art software and a custom-built portal, ... delivery of the seventy-five to one hundred thousand ...
Breaking Medicine News(10 mins):Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 2Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 3Health News:NLN Testing Services Announces Improved Delivery and Analytics Software and Newly Developed and Revised Exams 2
... , ... ... , , , ... ...
... patient records, funded by the Wellcome Trust, suggests that older ... GPs for investigation later than younger women. Researchers ... the General Practice Research Database (GPRD) and compared recorded diagnoses ... to see whether there was a difference in how older ...
... be linked to a slight rise in high blood pressure, ... drinkers can take heart from a series of studies presented ... , For example, coffee drinkers appear to have a lower ... indication that having a few cups every day increases the ...
... ... ... , , ... ...
... , ... ... ... ...
... in front of TV, computer linked to less bonding with ... -- Too much time in front of computers or televisions ... their parents and peers, a new study suggests. , The ... 15, who provided details about how they spent their free ...
Cached Medicine News:Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 2Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 3Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 4Health News:Study finds delay in referrals for older women with ovarian cancer 2Health News:Study finds delay in referrals for older women with ovarian cancer 3Health News:Coffee Is Generally Heart-Friendly 2Health News:Coffee Is Generally Heart-Friendly 3Health News:2010 Caring Coalition Conference Welcomes Author Gail Sheehy 2Health News:2010 Caring Coalition Conference Welcomes Author Gail Sheehy 3Health News:Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009 2Health News:Screen Time May Take a Toll on Kids' Relationships 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: